Former Republican Virginia Rep. Eric Cantor — the establishment figure who lost his 2014 primary in a stunning Tea Party upset — has been tapped as the next president and CEO of the Pharmaceutical Research and Manufacturers of America.
PhRMA, the top drug industry lobbying group, announced Tuesday that Cantor will assume the role effective Nov. 9. The appointment represents a significant career move for the former congressman and places him at the helm of one of Washington’s most powerful and well-funded trade associations at a time when drug pricing and pharmaceutical industry practices remain under intense scrutiny from both political parties.
Cantor represented Virginia’s 7th congressional district from 2000 to 2014 and served as House majority leader from 2011 to 2014 — before losing re-election to Tea Party-backed challenger Dave Brat by double digits in one of the biggest upsets in modern congressional history. His defeat sent shockwaves through the Republican establishment and was widely viewed as a turning point that illustrated the internal tensions within the GOP between its traditional leadership and the insurgent grassroots movement that would later help pave the way for significant shifts in the party’s direction.
The American biopharmaceutical industry leads the world. PhRMA’s member companies operate at the cutting edge of science and technology seeking novel treatments and cures for both chronic and rare diseases.
PhRMA Board of Directors Chair Rob Davis said in a statement that Cantor is “well respected among policy leaders in Washington and around the world, with a long track record of working effectively across the political spectrum.” The organization represents major pharmaceutical manufacturers and has historically been one of the most active lobbying forces on Capitol Hill, advocating for policies that protect drug patents and oppose government price controls while also promoting investment in biomedical research and innovation.
“Eric’s unique combination of global business acumen coupled with policy and political experience at the highest levels of government [makes] him an ideal person to lead PhRMA during this critical next chapter,” Davis added. The selection of a former member of House leadership underscores the industry’s continued emphasis on maintaining strong relationships with policymakers as it faces ongoing debates over drug costs and access.
We are excited to announce Eric Cantor as our next president and CEO.
Eric is well respected among policy leaders in Washington and around the world, with a long track record of working effectively across the political spectrum in support of biomedical research and patients’…
— PhRMA (@PhRMA) September 29, 2026
Cantor was expected to be a candidate for Speaker of the House before the 2014 upset. His loss effectively ended what had been a meteoric rise through Republican ranks and eliminated what many observers believed would be his eventual ascension to the speakership. Brat, who defeated him, would go on to lose re-election two cycles later to now-Democratic Virginia Gov. Abigail Spanberger. The district’s political transformation reflected broader demographic and ideological changes in Virginia’s suburban areas during that period.
Since departing Congress, Cantor has served as vice chairman and managing director at global investment bank Moelis & Company. This financial sector experience, combined with his extensive knowledge of legislative processes and relationships with current and former members of Congress, positions him as a bridge between the business community and government regulators—a critical skill set for leading a major trade association navigating complex policy challenges.
According to PhRMA’s announcement, Cantor “laid the groundwork for the passage of the 21st Century Cures Act, a landmark bill with bipartisan support that provided a significant increase in funding for the National Institutes of Health and included Food and Drug Administration reforms designed to speed medicine approvals to get them to patients faster.” This legislative achievement demonstrates his ability to build coalitions around healthcare innovation issues that align closely with the pharmaceutical industry’s priorities.
In his statement, Cantor said he’s “honored to join in the industry’s efforts to expand patient access, leverage the promise of AI to speed discovery, and be a champion for the hundreds of thousands of Americans working in the biopharmaceutical industry whose science improves, extends, and saves lives.” His remarks signal that PhRMA will continue to frame industry objectives around patient benefits and scientific advancement as it engages with policymakers on both sides of the aisle.
The announcement comes after PhRMA said in April that its current President and CEO Stephen Ubl notified the group’s board of his plans to step down at the end of 2026. The transition period allows for continuity in the organization’s operations as it prepares for what are likely to be contentious policy debates in the coming years over drug pricing, Medicare negotiations, and pharmaceutical regulation.
